{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:01:54Z","timestamp":1768032114763,"version":"3.49.0"},"reference-count":108,"publisher":"The Fukushima Society of Medical Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FJMS","Fukushima J. Med. Sci."],"published-print":{"date-parts":[[2026]]},"DOI":"10.5387\/fms.25-00009","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T22:07:58Z","timestamp":1756764478000},"page":"1-14","source":"Crossref","is-referenced-by-count":0,"title":["Development of combinatorial immunotherapy for patients with advanced gastric cancer from the perspective of immunosuppressive mechanisms in the tumor microenvironment"],"prefix":"10.5387","volume":"72","author":[{"given":"Kosaku","family":"Mimura","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine"},{"name":"Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kono","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3342","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kang YK, Boku N, Satoh T, <i>et al.<\/i> Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2):a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, <b>390<\/b>:2461-2471, 2017.","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"2","unstructured":"2. Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ,  <i>et al.<\/i> Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061):a randomised, open-label, controlled, phase 3 trial. Lancet, <b>392<\/b>:123-133, 2018."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Choi YY, Kim H, Shin SJ, <i>et al.<\/i> Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II\/III Gastric Cancer:Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg, <b>270<\/b>:309-316, 2019.","DOI":"10.1097\/SLA.0000000000002803"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chao J, Fuchs CS, Shitara K, <i>et al.<\/i> Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA oncology, <b>7<\/b>:895-902, 2021.","DOI":"10.1001\/jamaoncol.2021.0275"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chung HC, Kang YK, Chen Z,  <i>et al.<\/i> Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063):A randomized, open-label, phase 3 trial in Asian patients. Cancer, <b>128<\/b>:995-1003, 2022.","DOI":"10.1002\/cncr.34019"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chung HC, Arkenau HT, Lee J, <i>et al.<\/i> Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. Journal for immunotherapy of cancer, <b>7<\/b>:30, 2019.","DOI":"10.1186\/s40425-019-0508-1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Moehler M, Dvorkin M, Boku N, <i>et al.<\/i> Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers:Results From JAVELIN Gastric 100. Journal of clinical oncology:official journal of the American Society of Clinical Oncology, <b>39<\/b>:966-977, 2021.","DOI":"10.1200\/JCO.20.00892"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bang YJ, Ruiz EY, Van Cutsem E, <i>et al.<\/i> Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer:primary analysis of JAVELIN Gastric 300. Annals of oncology: official journal of the European Society for Medical Oncology, <b>29<\/b>:2052-2060, 2018.","DOI":"10.1093\/annonc\/mdy264"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Janjigian YY, Shitara K, Moehler M, <i>et al.<\/i> First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649):a randomised, open-label, phase 3 trial. Lancet, <b>398<\/b>:27-40, 2021.","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kang YK, Chen LT, Ryu MH, <i>et al.<\/i> Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4):a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, <b>23<\/b>:234-247, 2022.","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hinshaw DC, Shevde LA. The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer research, <b>79<\/b>:4557-4566, 2019.","DOI":"10.1158\/0008-5472.CAN-18-3962"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Li X, Liu R, Su X, <i>et al.<\/i> Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Molecular cancer, <b>18<\/b>:177, 2019.","DOI":"10.1186\/s12943-019-1102-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Consonni FM, Bleve A, Totaro MG, <i>et al.<\/i> Heme catabolism by tumor-associated macrophages controls metastasis formation. Nature immunology, <b>22<\/b>:595-606, 2021.","DOI":"10.1038\/s41590-021-00921-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ito M, Mimura K, Nakajima S, <i>et al.<\/i> M2 tumor-associated macrophages resist to oxidative stress through heme oxygenase-1 in the colorectal cancer tumor microenvironment. Cancer immunology, immunotherapy:CII, <b>72<\/b>:2233-2244, 2023.","DOI":"10.1007\/s00262-023-03406-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Min AKT, Mimura K, Nakajima S, <i>et al.<\/i> Therapeutic potential of anti-VEGF receptor 2 therapy targeting for M2-tumor-associated macrophages in colorectal cancer. Cancer immunology, immunotherapy:CII, <b>70<\/b>:289-298, 2021.","DOI":"10.1007\/s00262-020-02676-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature, <b>480<\/b>:480-489, 2011.","DOI":"10.1038\/nature10673"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nature reviews. Immunology, <b>6<\/b>:295-307, 2006.","DOI":"10.1038\/nri1806"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Current opinion in immunology, <b>27<\/b>:1-7, 2014.","DOI":"10.1016\/j.coi.2013.12.005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Itahashi K, Irie T, Yuda J, <i>et al.<\/i> BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Science immunology, <b>7<\/b>:eabk0957, 2022.","DOI":"10.1126\/sciimmunol.abk0957"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell research, <b>27<\/b>:109-118, 2017.","DOI":"10.1038\/cr.2016.151"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nature immunology, <b>19<\/b>:108-119, 2018.","DOI":"10.1038\/s41590-017-0022-x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer cell, <b>27<\/b>:462-472, 2015.","DOI":"10.1016\/j.ccell.2015.02.015"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Fukumura D, Kloepper J, Amoozgar Z, <i>et al.<\/i> Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol, <b>15<\/b>:325-340, 2018.","DOI":"10.1038\/nrclinonc.2018.29"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kono K, Mimura K, Kiessling R. Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell death &amp; disease, <b>4<\/b>:e688, 2013.","DOI":"10.1038\/cddis.2013.207"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity, <b>39<\/b>:1-10, 2013.","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Krysko DV, Garg AD, Kaczmarek A, <i>et al.<\/i> Immunogenic cell death and DAMPs in cancer therapy. Nature Reviews Cancer, <b>12<\/b>:860-875, 2012.","DOI":"10.1038\/nrc3380"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Hwang WL, Pike LRG, Royce TJ, <i>et al.<\/i> Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol, <b>15<\/b>:477-494, 2018.","DOI":"10.1038\/s41571-018-0046-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Weichselbaum RR, Liang H, Deng L, <i>et al.<\/i> Radiotherapy and immunotherapy:a beneficial liaison? Nat Rev Clin Oncol, <b>14<\/b>:365-379, 2017.","DOI":"10.1038\/nrclinonc.2016.211"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Zhai J, Gu X, Liu Y, <i>et al.<\/i> Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy:An update review. Frontiers in pharmacology, <b>14<\/b>:1152934, 2023.","DOI":"10.3389\/fphar.2023.1152934"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kopecka J, Salaroglio IC, Righi L, <i>et al.<\/i> Loss of C\/EBP-\u03b2 LIP drives cisplatin resistance in malignant pleural mesothelioma. Lung cancer (Amsterdam, Netherlands), <b>120<\/b>:34-45, 2018.","DOI":"10.1016\/j.lungcan.2018.03.022"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Spranger S,  Gajewski T. Rational combinations of immunotherapeutics that target discrete pathways. Journal for immunotherapy of cancer, <b>1<\/b>:16, 2013.","DOI":"10.1186\/2051-1426-1-16"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Wieder T, Eigentler T, Brenner E, <i>et al.<\/i> Immune checkpoint blockade therapy. The Journal of allergy and clinical immunology, <b>142<\/b>:1403-1414, 2018.","DOI":"10.1016\/j.jaci.2018.02.042"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Linsley PS, Brady W, Urnes M, <i>et al.<\/i> CTLA-4 is a second receptor for the B cell activation antigen B7. The Journal of experimental medicine, <b>174<\/b>:561-569, 1991.","DOI":"10.1084\/jem.174.3.561"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Walunas TL, Lenschow DJ, Bakker CY, <i>et al.<\/i> CTLA-4 can function as a negative regulator of T cell activation. Immunity, <b>1<\/b>:405-413, 1994.","DOI":"10.1016\/1074-7613(94)90071-X"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Agata Y, Kawasaki A, Nishimura H, <i>et al.<\/i> Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. International immunology, <b>8<\/b>:765-772, 1996.","DOI":"10.1093\/intimm\/8.5.765"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nature reviews. Immunology, <b>18<\/b>:153-167, 2018.","DOI":"10.1038\/nri.2017.108"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kawakami H, Hironaka S, Esaki T, <i>et al.<\/i> An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G\/CA209-7W7). Cancers, <b>13<\/b>:2021.","DOI":"10.3390\/cancers13040805"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Muro K, Kawakami H, Kadowaki S,    <i>et al.<\/i> 1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor:First results of the NO LIMIT study (WJOG13320G\/CA209-7W7). Annals of Oncology, <b>34<\/b>:S852-S853, 2023.","DOI":"10.1016\/j.annonc.2023.09.1426"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Andr\u00e9 T, Tougeron D, Piessen G, <i>et al.<\/i> Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair\/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma:The GERCOR NEONIPIGA Phase II Study. Journal of clinical oncology:official journal of the American Society of Clinical Oncology, <b>41<\/b>:255-265, 2023.","DOI":"10.1200\/JCO.22.00686"},{"key":"40","unstructured":"40. Tougeron D, Dahan L, Evesque L, <i>et al.<\/i> FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial. JAMA oncology, <b>10<\/b>:709-717, 2024."},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Stein A, Paschold L, Tintelnot J, <i>et al.<\/i> Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma:The AIO INTEGA Randomized Clinical Trial. JAMA oncology, <b>8<\/b>:1150-1158, 2022.","DOI":"10.1001\/jamaoncol.2022.2228"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Bang YJ, Van Cutsem E, Feyereislova A,    <i>et al.<\/i> Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3, open-label, randomised controlled trial. Lancet, <b>376<\/b>:687-697, 2010.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Shitara K, Ajani JA, Moehler M, <i>et al.<\/i> Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature, <b>603<\/b>:942-948, 2022.","DOI":"10.1038\/s41586-022-04508-4"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Jiang Y, Li Y, Zhu, B. T-cell exhaustion in the tumor microenvironment. Cell death &amp; disease, <b>6<\/b>:e1792, 2015.","DOI":"10.1038\/cddis.2015.162"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT:Distinct functions in immune regulation. Immunity, <b>57<\/b>:206-222, 2024.","DOI":"10.1016\/j.immuni.2024.01.010"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Mimura K, Kua LF, Xiao JF, <i>et al.<\/i> Combined inhibition of PD-1\/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models. Gastric cancer:official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, <b>24<\/b>:611-623, 2021.","DOI":"10.1007\/s10120-020-01151-8"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. He W, Zhang H, Han F, <i>et al.<\/i> CD155T\/TIGIT Signaling Regulates CD8(+) T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. Cancer research, <b>77<\/b>:6375-6388, 2017.","DOI":"10.1158\/0008-5472.CAN-17-0381"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Wang JB, Li P, Liu XL, <i>et al.<\/i> An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer. Nature communications, <b>11<\/b>:6352, 2020.","DOI":"10.1038\/s41467-020-20260-7"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Liu X, Xu C, Guo T, <i>et al.<\/i> Clinical significance of CD155 expression and correlation with cellular components of tumor microenvironment in gastric adenocarcinoma. Frontiers in immunology, <b>14<\/b>:1173524, 2023.","DOI":"10.3389\/fimmu.2023.1173524"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Wang D, Gu Y, Yan X, <i>et al.<\/i> Role of CD155\/TIGIT in Digestive Cancers:Promising Cancer Target for Immunotherapy. Frontiers in oncology, <b>12<\/b>:844260, 2022.","DOI":"10.3389\/fonc.2022.844260"},{"key":"51","unstructured":"51. Guo Y, Chu HZ, Xu JG. Research progress of immune heckpoint LAG-3 in gastric cancer:a narrative review. European review for medical and pharmacological sciences, <b>27<\/b>:248-255, 2023."},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4:breakthroughs or backups. Nature immunology, <b>20<\/b>:1425-1434, 2019.","DOI":"10.1038\/s41590-019-0512-0"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Ruffo E, Wu RC, Bruno TC, <i>et al.<\/i> Lymphocyte-activation gene 3 (LAG3):The next immune checkpoint receptor. Seminars in immunology, <b>42<\/b>:101305, 2019.","DOI":"10.1016\/j.smim.2019.101305"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Maruhashi T, Sugiura D, Okazaki IM,    <i>et al.<\/i> LAG-3:from molecular functions to clinical applications. Journal for immunotherapy of cancer, <b>8<\/b>:2020.","DOI":"10.1136\/jitc-2020-001014"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Kouo T, Huang L, Pucsek AB, <i>et al.<\/i> Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer immunology research, <b>3<\/b>:412-423, 2015.","DOI":"10.1158\/2326-6066.CIR-14-0150"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Xu F, Liu J, Liu D, <i>et al.<\/i> LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer research, <b>74<\/b>:3418-3428, 2014.","DOI":"10.1158\/0008-5472.CAN-13-2690"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Wang J, Sanmamed MF, Datar I, <i>et al.<\/i> Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell, <b>176<\/b>:334-347.e312, 2019.","DOI":"10.1016\/j.cell.2018.11.010"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nature immunology, <b>24<\/b>:1415-1422, 2023.","DOI":"10.1038\/s41590-023-01569-z"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Rha SY, Miller WH, Miguel MJd, <i>et al.<\/i> Phase 1 trial of the anti-LAG3 antibody favezelimab plus pembrolizumab in advanced gastric cancer. Journal of Clinical Oncology, <b>41<\/b>:394-394, 2023.","DOI":"10.1200\/JCO.2023.41.4_suppl.394"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Hegewisch   -Becker S, Mendez G, Chao J, <i>et al.<\/i> First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma:The Phase II RELATIVITY-060 Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, <b>42<\/b>:2080-2093, 2024.","DOI":"10.1200\/JCO.23.01636"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Kelly RJ, Landon BV, Zaidi AH, <i>et al.<\/i> Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer:a phase Ib trial and ctDNA analyses. Nat Med, <b>30<\/b>:1023-1034, 2024.","DOI":"10.1038\/s41591-024-02877-z"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Hudson WH, Gensheimer J, Hashimoto M, <i>et al.<\/i> Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1(+) Stem-like CD8(+) T Cells during Chronic Infection. Immunity, <b>51<\/b>:1043-1058.e1044, 2019.","DOI":"10.1016\/j.immuni.2019.11.002"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Im SJ, Hashimoto M, Gerner MY, <i>et al.<\/i> Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature, <b>537<\/b>:417-421, 2016.","DOI":"10.1038\/nature19330"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Jin HT, Anderson AC, Tan WG, <i>et al.<\/i> Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, <b>107<\/b>:14733-14738, 2010.","DOI":"10.1073\/pnas.1009731107"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Sakuishi K, Apetoh L, Sullivan JM, <i>et al.<\/i> Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of experimental medicine, <b>207<\/b>:2187-2194, 2010.","DOI":"10.1084\/jem.20100643"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Ngiow SF, von Scheidt B, Akiba H, <i>et al.<\/i> Anti-TIM3 antibody promotes T cell IFN-\u03b3-mediated antitumor immunity and suppresses established tumors. Cancer research, <b>71<\/b>:3540-3551, 2011.","DOI":"10.1158\/0008-5472.CAN-11-0096"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Curigliano G, Gelderblom H, Mach N,    <i>et al.<\/i> Phase I\/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research, <b>27<\/b>:3620-3629, 2021.","DOI":"10.1158\/1078-0432.CCR-20-4746"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Harding JJ, Moreno V, Bang YJ, <i>et al.<\/i> Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors:A Phase Ia\/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clinical cancer research:an official journal of the American Association for Cancer Research, <b>27<\/b>:2168-2178, 2021.","DOI":"10.1158\/1078-0432.CCR-20-4405"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Yu X, Harden K, Gonzalez LC, <i>et al.<\/i> The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nature immunology, <b>10<\/b>:48-57, 2009.","DOI":"10.1038\/ni.1674"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. Journal for immunotherapy of cancer, <b>8<\/b>:2020.","DOI":"10.1136\/jitc-2020-000957"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Banta KL, Xu X, Chitre AS, <i>et al.<\/i> Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity, <b>55<\/b>:512-526.e519, 2022.","DOI":"10.1016\/j.immuni.2022.02.005"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Joller N, Hafler JP, Brynedal B, <i>et al.<\/i> Cutting edge:TIGIT has T cell-intrinsic inhibitory functions. Journal of immunology (Baltimore, Md.:1950), <b>186<\/b>:1338-1342, 2011.","DOI":"10.4049\/jimmunol.1003081"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Johnston RJ, Comps   -Agrar L, Hackney J, <i>et al.<\/i> The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer cell, <b>26<\/b>:923-937, 2014.","DOI":"10.1016\/j.ccell.2014.10.018"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Shitara K, Golan T, Mileham K, <i>et al.<\/i> PD-3 Phase 1 trial of vibostolimab plus pembrolizumab for PD-1\/PD-L1 inhibitor-naive advanced gastric cancer:The KEYVIBE-001 trial. Annals of Oncology, <b>33<\/b>:S240, 2022.","DOI":"10.1016\/j.annonc.2022.04.081"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Kim SH, Lee GW, Shim BY, <i>et al.<\/i> AdvanTIG-105:A phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric\/gastroesophageal adenocarcinoma (GC\/GEJC). Journal of Clinical Oncology, <b>41<\/b>:4028-4028, 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.4028"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Janjigian YY, Oh DY, Pelster M, <i>et al.<\/i> EDGE-Gastric Arm A1:Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer. Journal of Clinical Oncology, <b>41<\/b>:433248-433248, 2023.","DOI":"10.1200\/JCO.2023.41.36_suppl.433248"},{"key":"77","unstructured":"77. Shen L, Zhang Y, Li Z, <i>et al.<\/i> First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma:a randomized, double-blind, phase 3 trial. Nat Med, 2025."},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Catenacci DV, Rosales M, Chung HC,    <i>et al.<\/i> MAHOGANY:margetuximab combination in HER2+ unresectable\/metastatic gastric\/gastroesophageal junction adenocarcinoma. Future oncology (London, England), <b>17<\/b>:1155-1164, 2021.","DOI":"10.2217\/fon-2020-1007"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Tsumuraya H, Mimura K, Nakajima S, <i>et al.<\/i> Tumor Infiltrating Effector Regulatory T Cells Express VEGF Receptor 2 in Patients With Colorectal Cancer. Anticancer research, <b>44<\/b>:2933-2941, 2024.","DOI":"10.21873\/anticanres.17105"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Tada Y, Togashi Y, Kotani D, <i>et al.<\/i> Targeting VEGFR2 with Ramucirumab strongly impacts effector\/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment. Journal for immunotherapy of cancer, <b>6<\/b>:106, 2018.","DOI":"10.1186\/s40425-018-0403-1"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Fukuoka S, Hara H, Takahashi N, <i>et al.<\/i> Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer:An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). Journal of clinical oncology:official journal of the American Society of Clinical Oncology, <b>38<\/b>:2053-2061, 2020.","DOI":"10.1200\/JCO.19.03296"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Cousin S, Metges JP, Bellera CA,    <i>et al.<\/i> REGOMUNE:A phase II study of regorafenib plus avelumab in solid tumors\u2014Results of the oesophageal or gastric carcinoma (OGC) cohort. Journal of Clinical Oncology, <b>40<\/b>:4060-4060, 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.4060"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. Cytryn SL, Moy RH, Cowzer D, <i>et al.<\/i> First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA:a single-arm, single-centre, phase 2 trial. The Lancet Oncology, <b>24<\/b>:1073-1082, 2023.","DOI":"10.1016\/S1470-2045(23)00358-3"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. Pavlakis N, Shitara K, Sjoquist KM, <i>et al.<\/i> INTEGRATE IIb:A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC). Journal of Clinical Oncology, <b>40<\/b>:TPS366-TPS366, 2022.","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS366"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. Herbst RS, Arkenau HT, Santana-Davila R, <i>et al.<\/i> Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF):a multicohort, non-randomised, open-label, phase 1a\/b trial. The Lancet Oncology, <b>20<\/b>:1109-1123, 2019.","DOI":"10.1016\/S1470-2045(19)30458-9"},{"key":"86","doi-asserted-by":"crossref","unstructured":"86. Chau I, Penel N, Soriano AO, <i>et al.<\/i> Ramucirumab in Combination with Pembrolizumab in Treatment-Na\u00efve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a\/b JVDF Trial.   in Cancers, Vol. 12 (2020).","DOI":"10.3390\/cancers12102985"},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. Bang YJ, Golan T, Dahan L, <i>et al.<\/i> Ramucirumab and durvalumab for previously treated, advanced non\u2013small-cell lung cancer, gastric\/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma:An open-label, phase Ia\/b study (JVDJ). European Journal of Cancer, <b>137<\/b>:272-284, 2020.","DOI":"10.1016\/j.ejca.2020.06.007"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. Hara H, Shoji H, Takahari D, <i>et al.<\/i> Phase I\/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study). Journal of Clinical Oncology, <b>37<\/b>:129-129, 2019.","DOI":"10.1200\/JCO.2019.37.4_suppl.129"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. Nakajima TE, Kadowaki S, Minashi K,    <i>et al.<\/i>Multicenter Phase I\/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. Clinical Cancer Research, <b>27<\/b>:1029-1036, 2021.","DOI":"10.1158\/1078-0432.CCR-20-3559"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. Thuss-Patience P, H\u00f6gner A, Goekkurt E, <i>et al.<\/i> Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma:The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial. JAMA Network Open, <b>7<\/b>:e2352830-e2352830, 2024.","DOI":"10.1001\/jamanetworkopen.2023.52830"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. Xu J, Zhang Y, Jia R, <i>et al.<\/i> Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer:An Open-label, Dose Escalation and Expansion Study. Clinical Cancer Research, <b>25<\/b>:515-523, 2019.","DOI":"10.1158\/1078-0432.CCR-18-2484"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. Saeed A, Colby S, Oberstein PE, <i>et al.<\/i> SWOG S2303:Randomized phase II\/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS \u2265 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE). Journal of Clinical Oncology, <b>42<\/b>:TPS430-TPS430, 2024.","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS430"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. Li S, Yu W, Xie F, <i>et al.<\/i> Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nature communications, <b>14<\/b>:8, 2023.","DOI":"10.1038\/s41467-022-35431-x"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. Chen L, Ye Z, Liu G, <i>et al.<\/i> 85P Tislelizumab combined with apatinib and oxaliplatin plus S1 as neoadjuvant therapy for Borrmann IV large Borrmann III type and bulky N positive advanced gastric cancer:A single-arm multicenter trial (TAOS-3B-Trial). Immuno-Oncology and Technology, <b>16<\/b>:100189, 2022.","DOI":"10.1016\/j.iotech.2022.100189"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. Kawazoe A, Fukuoka S, Nakamura Y, <i>et al.<\/i> Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706):an open-label, single-arm, phase 2 trial. The Lancet Oncology, <b>21<\/b>:1057-1065, 2020.","DOI":"10.1016\/S1470-2045(20)30271-0"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. Cohen DJ, Tabernero J, Cutsem EV, <i>et al.<\/i> A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced\/metastatic gastroesophageal adenocarcinoma:LEAP-015. Journal of Clinical Oncology, <b>40<\/b>:TPS369-TPS369, 2022.","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS369"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. Suzuki Y, Mimura K, Yoshimoto Y, <i>et al.<\/i> Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer research, <b>72<\/b>:3967-3976, 2012.","DOI":"10.1158\/0008-5472.CAN-12-0851"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. Nakajima S, Mimura K, Kaneta A, <i>et al.<\/i> Radiation-Induced Remodeling of the Tumor Microenvironment Through Tumor Cell-Intrinsic Expression of cGAS-STING in Esophageal Squamous Cell Carcinoma. International journal of radiation oncology, biology, physics, <b>115<\/b>:957-971, 2023.","DOI":"10.1016\/j.ijrobp.2022.10.028"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. Mimura K, Ogata T, Nguyen PHD, <i>et al.<\/i> Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer. Journal for immunotherapy of cancer, <b>12<\/b>:e008385, 2024.","DOI":"10.1136\/jitc-2023-008385"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. Spigel DR, Faivre-Finn C, Gray JE, <i>et al.<\/i> Five-Year Survival Outcomes From the PACIFIC Trial:Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of clinical oncology:official journal of the American Society of Clinical Oncology, <b>40<\/b>:1301-1311, 2022.","DOI":"10.1200\/JCO.21.01308"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. Lorusso D, Xiang Y, Hasegawa K, <i>et al.<\/i> Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18):overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, <b>404<\/b>:1321-1332, 2024.","DOI":"10.1016\/S0140-6736(24)01808-7"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. Kelly RJ, Ajani JA, Kuzdzal J, <i>et al.<\/i> Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med, <b>384<\/b>:1191-1203, 2021.","DOI":"10.1056\/NEJMoa2032125"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. Lee NY, Ferris RL, Psyrri A, <i>et al.<\/i> Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck:a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Oncology, <b>22<\/b>:450-462, 2021.","DOI":"10.1016\/S1470-2045(20)30737-3"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. Monk BJ, Toita T, Wu X, <i>et al.<\/i> Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA):a randomised, double-blind, phase 3 trial. The Lancet Oncology, <b>24<\/b>:1334-1348, 2023.","DOI":"10.1016\/S1470-2045(23)00479-5"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. Mimura K, Ogata T, Yoshimoto Y, <i>et al.<\/i> Phase I\/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer. Communications medicine, <b>3<\/b>:111, 2023.","DOI":"10.1038\/s43856-023-00343-4"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. Qi C, Liu C, Gong J, <i>et al.<\/i> Claudin18.2-specific CAR T cells in gastrointestinal cancers:phase 1 trial final results. Nat Med, <b>30<\/b>:2224-2234, 2024.","DOI":"10.1038\/s41591-024-03037-z"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. Lowery FJ, Goff SL, Gasmi B, <i>et al.<\/i> Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers:a phase 2 trial. Nat Med, 2025.","DOI":"10.1038\/s41591-025-03627-5"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. Guo Z, Yuan Y, Chen C <i>et al.<\/i> Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer. NPJ precision oncology, <b>6<\/b>:34, 2022.","DOI":"10.1038\/s41698-022-00279-3"}],"container-title":["FUKUSHIMA JOURNAL OF MEDICAL SCIENCE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/72\/1\/72_25-00009\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:41:52Z","timestamp":1768020112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/fms\/72\/1\/72_25-00009\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":108,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5387\/fms.25-00009","relation":{},"ISSN":["0016-2590","2185-4610"],"issn-type":[{"value":"0016-2590","type":"print"},{"value":"2185-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"25-00009"}}